MGC's Cannabinoid Drugs For Epilepsy, Dementia and Alzheimer's To Reach Several European Countries

MGC Pharmaceuticals Ltd. MGCLF MXC MXC has signed an exclusive distribution agreement with Sciensus Rare, for the distribution of CannEpil and CogniCann.

The agreement is for the distribution in key European territories and the UK for CannEpil, used to treat drug resistant epilepsy, and CogniCann, used to treat patients with dementia and Alzheimer's disease.

Sciensus Rare is an international pharmaceutical company based in the Netherlands, specializing in the provision of rare disease medicines through decentralized clinical trials and medical early access programs, with over 30-year of experience in providing health care services, and expanding medical access for products in Western Europe.

Under the terms of the distribution agreement, Sciensus Rare has been appointed the exclusive distributor of CannEpil and CogniCann in Denmark, France, Italy, Spain, Luxembourg, and the United Kingdom, for an initial 4-year term. After the initial 12 months of the agreement, Sciensus Rare will be subject to minimum purchase order requirements to maintain its exclusive distributor status. The Parties have agreed that MGC Pharma will continue to be responsible for seeking market authorization in these territories, while Sciensus Rare will be responsible for applications to early access programs and named patient programs.

Roby Zomer, managing director and CEO of MGC Pharma, stated:

"Sciensus Rare is an excellent pharmaceutical service company, with the experience and expertise necessary to increase clinical access for both CannEpil and CogniCann to those patients who are most in need. This is another important step in widening patient access to our pharmaceutical products, and puts in place a long term plan to build the distribution networks required in Western Europe, one of the most important pharmaceutical markets in the world."